90 related articles for article (PubMed ID: 1433263)
1. Comparison of protection from homologous cell-free vs cell-associated SIV challenge afforded by inactivated whole SIV vaccines.
Heeney JL; de Vries P; Dubbes R; Koornstra W; Niphuis H; ten Haaft P; Boes J; Dings ME; Morein B; Osterhaus AD
J Med Primatol; 1992; 21(2-3):126-30. PubMed ID: 1433263
[TBL] [Abstract][Full Text] [Related]
2. Comparison of protection afforded by whole virus ISCOM versus MDP adjuvanted formalin-inactivated SIV vaccines from IV cell-free or cell-associated homologous challenge.
Osterhaus A; de Vries P; Morein B; Akerblom L; Heeney J
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1507-10. PubMed ID: 1466991
[TBL] [Abstract][Full Text] [Related]
3. A formalin inactivated whole SIVmac vaccine in Ribi adjuvant protects against homologous and heterologous SIV challenge.
Putkonen P; Thorstensson R; Cranage M; Nilsson C; Ghavamzadeh L; Albert J; Greenaway P; Biberfeld G
J Med Primatol; 1992; 21(2-3):108-12. PubMed ID: 1433260
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of live-attenuated and whole-inactivated simian immunodeficiency virus vaccines against vaginal challenge with virulent SIV.
Marthas ML; Miller CJ; Sutjipto S; Higgins J; Torten J; Lohman BL; Unger RE; Ramos RA; Kiyono H; McGhee JR
J Med Primatol; 1992; 21(2-3):99-107. PubMed ID: 1433273
[TBL] [Abstract][Full Text] [Related]
5. Protection of rhesus macaques from SIV infection by immunization with different experimental SIV vaccines.
de Vries P; Heeney JL; Boes J; Dings ME; Hulskotte EG; Dubbes R; Koornstra W; ten Haaft P; Akerblom L; Eriksson S
Vaccine; 1994 Nov; 12(15):1443-52. PubMed ID: 7887023
[TBL] [Abstract][Full Text] [Related]
6. Long-lasting protection by live attenuated simian immunodeficiency virus in cynomolgus monkeys: no detection of reactivation after stimulation with a recall antigen.
Sernicola L; Corrias F; Koanga-Mogtomo ML; Baroncelli S; Di Fabio S; Maggiorella MT; Belli R; Michelini Z; Macchia I; Cesolini A; Cioè L; Verani P; Titti F
Virology; 1999 Apr; 256(2):291-302. PubMed ID: 10191194
[TBL] [Abstract][Full Text] [Related]
7. Vaccine protection and reduced virus load from heterologous macaque-propagated SIV challenge.
Heeney JL; Holterman L; ten Haaft P; Dubbes R; Koornstra W; Teeuwsen V; Bourquin P; Norley S; Niphuis H
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S117-21. PubMed ID: 7865285
[TBL] [Abstract][Full Text] [Related]
8. Whole inactivated SIV vaccine grown on human cells fails to protect against homologous SIV grown on simian cells.
Putkonen P; Nilsson C; Hild K; Benthin R; Cranage M; Aubertin AM; Biberfeld G
J Med Primatol; 1993; 22(2-3):100-3. PubMed ID: 8411101
[TBL] [Abstract][Full Text] [Related]
9. A formalin inactivated whole SIV vaccine and a glycoprotein-enriched subunit vaccine confers protection against experimental challenge with pathogenic live SIV in rhesus monkeys.
Murphey-Corb M; Martin LN; Davison-Fairburn B; Montelaro RC; Miller M; West M; Ohkawa S; Baskin GB; Zhang JY; Putney S
Dev Biol Stand; 1990; 72():273-85. PubMed ID: 2282987
[No Abstract] [Full Text] [Related]
10. Protection against SIV infection in macaques by immunization with inactivated virus from the BK28 molecular clone, but not with BK28-derived recombinant env and gag proteins.
Mills KH; Page M; Chan WL; Kitchin P; Stott EJ; Taffs F; Jones W; Rose J; Ling C; Silvera P
J Med Primatol; 1992; 21(2-3):50-8. PubMed ID: 1433267
[TBL] [Abstract][Full Text] [Related]
11. Immunization with virion-derived glycoprotein 130 from HIV-2 or SIV protects macaques against challenge virus grown in human or simian cells or prepared ex vivo.
Stahl-Hennig C; Coulibaly C; Petry H; Voss G; Dittmer U; Bodemer W; Makoschey B; Jurkiewicz E; Lüke W; Hunsmann G
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S27-32. PubMed ID: 7865316
[TBL] [Abstract][Full Text] [Related]
12. Vaccine protection of rhesus macaques against simian immunodeficiency virus infection.
Carlson JR; McGraw TP; Keddie E; Yee JL; Rosenthal A; Langlois AJ; Dickover R; Donovan R; Luciw PA; Jennings MB
AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1239-46. PubMed ID: 2078406
[TBL] [Abstract][Full Text] [Related]
13. Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model.
Suh YS; Park KS; Sauermann U; Franz M; Norley S; Wilfingseder D; Stoiber H; Fagrouch Z; Heeney J; Hunsmann G; Stahl-Hennig C; Sung YC
Vaccine; 2006 Mar; 24(11):1811-20. PubMed ID: 16274888
[TBL] [Abstract][Full Text] [Related]
14. Vaccine-induced virus-neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with simian immunodeficiency virus SIVmac32H (J5).
Hulskotte EG; Geretti AM; Siebelink KH; van Amerongen G; Cranage MP; Rud EW; Norley SG; de Vries P; Osterhaus AD
J Virol; 1995 Oct; 69(10):6289-96. PubMed ID: 7666529
[TBL] [Abstract][Full Text] [Related]
15. SIV vaccine protection of rhesus monkeys.
Gardner MB; Carlson JR; Jennings M; Rosenthal A; Langlois A; Haynes B; Bolognesi D; Palker TJ
Biotechnol Ther; 1991; 2(1-2):9-19. PubMed ID: 1845125
[TBL] [Abstract][Full Text] [Related]
16. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P).
Kumar A; Lifson JD; Li Z; Jia F; Mukherjee S; Adany I; Liu Z; Piatak M; Sheffer D; McClure HM; Narayan O
Virology; 2001 Jan; 279(1):241-56. PubMed ID: 11145906
[TBL] [Abstract][Full Text] [Related]
17. Simian immunodeficiency virus (SIV) gp130 oligomers protect rhesus macaques (Macaca mulatta) against the infection with SIVmac32H grown on T-cells or derived ex vivo.
Luke W; Coulibaly C; Dittmer U; Voss G; Oesterle R; Makoschey B; Sauermann U; Jurkiewicz E; Stahl-Henning C; Petry H; Hunsmann G
Virology; 1996 Feb; 216(2):444-50. PubMed ID: 8607276
[TBL] [Abstract][Full Text] [Related]
18. Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIVmac251 rectal challenge: role of SIV-specific CD8+ T cell responses.
Malkevitch NV; Patterson LJ; Aldrich MK; Wu Y; Venzon D; Florese RH; Kalyanaraman VS; Pal R; Lee EM; Zhao J; Cristillo A; Robert-Guroff M
Virology; 2006 Sep; 353(1):83-98. PubMed ID: 16814356
[TBL] [Abstract][Full Text] [Related]
19. Immunization of Macaca fascicularis with inactivated SIV preparations: challenge with human- or monkey-derived SIV and the effects of a longer immunization schedule.
Titti F; Koanga Mogtomo ML; Borsetti A; Geraci A; Sernicola L; Panzini G; Turillazzi GP; Baroncelli S; Giovannetti A; Zamarchi R
J Med Primatol; 1993; 22(2-3):110-8. PubMed ID: 8411103
[TBL] [Abstract][Full Text] [Related]
20. Specific and non-specific immunity and protection of macaques against SIV infection.
Le Grand R; Vogt G; Vaslin B; Roques P; Théodoro F; Aubertin AM; Dormont D
Vaccine; 1992; 10(12):873-9. PubMed ID: 1455913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
